Introduction
About 3 to 5 million patients worldwide experience tendon injuries each year [
1]. Tendon healing is slow and often incomplete: the currently available techniques for surgical intervention and repair are inadequate [
2‐
5]. New procedures should be developed to produce better outcome. In this context, tissue engineering (the combination of cells, growth factors, and carriers into functional tissue) is a promising therapeutic option in tendon regenerative medicine.
Recently, cell-based, and especially stem cell-based, strategies for tendon regeneration have attracted enormous attention. Bone marrow mesenchymal stem cells (BMSCs) have been extensively studied, displaying tenogenic differentiation capacity [
6], and are currently the most widely used type of stem cell [
7,
8], since they have potential for improving tendon repair [
6], accelerating healing, and regenerating normal tissue. At present, however, BMSCs alone seem ineffective [
9,
10], and recent biological approaches, such as BMSCs in combination with growth factors, and specialized delivery systems are being explored to enhance tendon healing [
11‐
13].
Our previous reports have shown that tendons express thyroid hormone (TH) receptor isoforms and that T
3 and T
4 hormones enhance tenocyte proliferation in vitro [
14,
15]. Moreover, T
3 and T
4 contrast apoptosis in healthy tenocytes in a dose- and time-dependent manner [
14,
15]. THs (especially T
3) stimulate cellular proliferation and type I collagen formation, the major fibrillar collagen in tendons. Furthermore, we have shown that, in the presence of ascorbic acid (AA), T
3 increases collagen I expression, and additionally, T
3 also increases ECM protein secretion in the presence of AA and, in particular, biglycan and COMP (cartilage oligomeric matrix protein) expression [
14,
16,
17]. Robinson et al. recently demonstrated that biglycan is required for mechanical proprieties in the tendon and for collagen fiber realignment after loading [
18]. COMP is known to co-localize with collagen I [
19], and a marked reduction of COMP in tendon injury has recently been demonstrated, suggesting the possibility of its use as a marker for tendon injury [
20]. In addition, AA on its own triggers the proliferation of tendon-derived cells [
16,
17]. AA also decreases nitric oxide synthesis (NOS) in the same experimental condition. NOS inhibition exerts beneficial effects on tendon regeneration and function in a murine of Achilles tendon rupture [
21]. When AA is combined with T
3, it synergistically induces an increase in tenocyte proliferation [
17].
The role of thyroid hormones in stem cell function is still unclear and further study is required. Previous investigations have shown that the thyroid hormone T
3 exerts a dose-dependent effect on the chondrogenic and osteogenic differentiation of BMSC in female rats, promoting chondrogenic matrix formation and collagen synthesis respectively [
22,
23]. T
3 treatment increases the differentiation of BMSCs induced to cardiomyocytes and promotes their maturation [
24]. The combined treatment of BMSC with exercise and thyroid hormones enhances new neuronal cell generation and attenuates apoptosis in ischemia strokes in mice [
25].
There is some uncertainty as to whether BMSC transplantation alone is sufficient to achieve satisfactory outcomes in tendon repair and healing. Therefore, it is necessary to assess the effects of combining other therapies with cell therapy to increase their therapeutic efficacy in tendon injury. In trying to translate all these findings into clinical practice, it would be reasonable, first of all, to hypothesize that AA and T3 in combination would be beneficial to human tendon healing in vivo. Moreover, no studies have yet been performed to understand the influence of thyroid hormones on BMSCs in tendon regeneration, nor of thyroid hormones and BMSCs in combination with AA.
Therefore, the present pilot study, using a rat Achilles tendon injury model, aimed to verify the roles of rBMSC, AA, and T3 in promoting healing after local inoculation at the site of injury. rBMSC, AA, and T3 were used alone and in every possible combination and compared with an untreated control. After a period of 30 days, the efficacy of local administration of all combinations of rBMSCs, AA, and T3 on healing was evaluated.
Discussion
We wished to test the effect of local micro-injection of AA, T
3, and rBMSCs, individually and in every possible combination, on tendon healing in damaged rat tendons. Our investigation logically follows prior studies which demonstrated the relevance of ascorbic acid and T
3 in combination with the biological function of tenocytes. Novel preliminary findings demonstrate the efficacy of ascorbic acid in combination with the T
3 hormone in improving tendon healing, confirming our previous in vitro studies [
14,
16,
17]. Histological evaluation confirmed better restoration of normal tendon architecture with an optimal alignment of tendon fibers and blood vessels, although the continued presence of high cellularity suggests that the regenerative process was not complete. Furthermore, in the tendons treated with AA + T
3, the analysis of the collagen ratios demonstrated a higher expression of collagen type I, and lower expression of collagen type III, than in all the other groups, including the CTRL group. Comparison of the AA + T
3 treatment with the AA alone, and the T
3 alone, showed that the co-administration of AA and T
3 yielded greater beneficial effects than the administration of either separately. The histological score values and the collagen ratios were worse for AA alone, and for T
3 alone, than for the CTRL group, although they were better than for the rBMSC + AA group, the rBMSC + T
3 group, and the rBMSC + AA + T
3 group. This was not the case for the histological score value of the rBMSC group. The healing process of an injured tendon passes through three main phases, featuring distinctive cellular and molecular cascades: (i) inflammatory; (ii) reparative (proliferation), characterized by cellularity and matrix production, which is mostly collagen type III; and (iii) remodeling (consolidation and maturation), replacing collagen type III with collagen type I and fiber organization [
36]. Taken together, the results indicate that ascorbic acid acts in synergy with T
3 to accelerate tendon healing.
Our results agree not only with our own previous data, but also with other studies [
3,
37]. Ascorbic acid stimulates a wide range of tissue functions; it contributes not only to increased collagen synthesis and cross-linking, but also plays key roles in stem cell function, such as in the differentiation of mesenchymal stem cells into tenocytes [
37,
38]. Supplementation with ascorbic acid also enhances tendon healing in mouse models [
39]. Moreover, thyroid hormones are major determinants of tissue function, playing well-defined roles in cell signaling. The role of thyroid hormones in tenocyte physiology is a novel area of study in this field [
14,
15,
40,
41]. Moreover, THs regulate the function of stem cells, controlling self-renewal, proliferation, and differentiation. In vivo studies suggest high intracellular level requirement of T
3 to support normal myogenesis and muscle repair after cardiotoxin injury [
42]. All the animals in the groups treated with rBMSC healed less well than all the other groups, including the CTRL group, when analyzed histopathologically and histomorphologically. The group which received rBMSC only showed better results than the rBMSC + AA group, the rBMSC + T
3 group, and the rBMSC + AA + T
3 group. At present, the use of mesenchymal stem cells in tendon healing is still the subject of controversy, debate, and study. Indeed, only three BMSC-based therapies have shown favorable outcomes in rat studies with improved histological and biomechanical tendon properties [
43]. However, in accordance with our investigation, several other studies were not able to demonstrate beneficial effects of BMSC on tendon healing. Furthermore, no difference in collagen production or in extracellular matrix organization has been demonstrated. The source of stem cells for implantation is still under debate. In the present investigation, the cells used were derived from the bone marrow, but recent developments suggest that stem cells derived from the tendons themselves show the greatest promise to improve healing [
44]. Moreover, it should be underlined that growth factors in combination with the cells have recently been shown to require controlled spatiotemporal delivery to the repair site to improve tendon healing [
12,
44]. Consequently, greater enhancement of tendon healing could be obtained by specialized delivery approaches, for example, by tissue engineering using a variety of scaffolds [
12,
44]. The exact mechanisms of tendon healing and the precise roles that different cell types play in the process are, as yet, not clear, and further studies are necessary to develop a range of suitable techniques involving stem cells to favor and hasten tendon regeneration and repair [
45].
Our results do not confirm the findings of previous studies regarding the use of AA in combination with MSCs [
39,
46]. This is likely because of the different methodology and different model used and the different source of the stem cells. Kang et al. used AA to stimulate MSCs before transplantation in a mouse tendonitis model, using adipose-derived cells [
39]. Durant et al. used an in vitro model employing tendon-derived stem cells, which may have had some bearing on the results obtained [
46]. T
3 has not been used in previous in vivo studies. Hence, no direct comparisons can be made yet, and therefore, further work is required to understand the precise mechanisms involved and the full extent of possible benefits in any clinical applications which may be developed to improve, enhance, and/or accelerate tendon healing.
Conclusions
There are several limitations to the present pilot study. First, owing to our focus on histological and histomorphometric examination of repair, only one middle-term evaluation point was used. It remains inconclusive whether or not the effects of using BMSCs, AA, and T3 alone, and in every possible treatment combination, lead to short- and long-term structural and functional benefits to tendon healing. Secondly, the effectiveness of AA combined with T3 in improving strength and stiffness following the repair of rat tendons requires further analysis.
Despite these considerations, the present study would appear to [
14‐
17] confirm the hypothesis that AA used in combination with T
3 improves tendon healing in vivo, based upon the best histological score evaluation achieved and on collagen I and III ratio measurement. In the present investigation, for the first time, T
3 has been utilized for tendon healing in an animal model, and that, apart from our previous in vitro study, no other studies have been made that investigate the activity of T
3 in tendons. For this reason, our experimental model combining AA with T
3 and with BMSCs is unique to date. Our results must stimulate two further areas of investigation—on the one hand, into the comprehension of the underlying mechanistic processes of T
3 in a tendon environment and the associated complex interaction between T
3, AA, and BMSCs; secondly, our data suggest that AA in combination with T
3 could be used to develop possible cell-free therapy for improved tendon healing. Furthermore, it will be important to identify optimum delivery methods and doses of AA + T
3 to improve tendon healing and avoid potential toxicity and, ultimately, to translate this approach into clinical applications in humans.